Cargando…

Preparation and In Vitro, In Vivo Evaluation of Clarithromycin Microcapsules

PURPOSE: To develop and validate a method to prepare clarithromycin (CLM) microcapsules to mask the bitter taste and provide effective treatment, and evaluate the quality of microcapsules in detail, especially the in vitro and in vivo pharmacokinetics behavior. METHODS: CLM microcapsules were prepar...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Liandong, Liu, Wei, Li, Li, Zhao, Jiqiang, Yang, Xun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979207/
https://www.ncbi.nlm.nih.gov/pubmed/24825996
_version_ 1782310709720252416
author Hu, Liandong
Liu, Wei
Li, Li
Zhao, Jiqiang
Yang, Xun
author_facet Hu, Liandong
Liu, Wei
Li, Li
Zhao, Jiqiang
Yang, Xun
author_sort Hu, Liandong
collection PubMed
description PURPOSE: To develop and validate a method to prepare clarithromycin (CLM) microcapsules to mask the bitter taste and provide effective treatment, and evaluate the quality of microcapsules in detail, especially the in vitro and in vivo pharmacokinetics behavior. METHODS: CLM microcapsules were prepared using ethyl cellulose as matrix material by an emulsion solvent diffusion method. The physicochemical property, in vitro release study, sensory test and stability test were evaluated. Self-made CLM dry suspension or conventional tablets containing 250 mg of CLM were orally administered with 250 mL of water. The plasma concentration was determined and the pharmacokinetic parameters were calculated by non-compartmental methods. RESULTS: Stable microcapsules could be prepared using ethyl cellulose as matrix material. The quality evaluation of prepared microcapsules was qualified, and the pharmacokinetic parameters of dry suspensions and conventional tablets were as following. C(max) were 1.32±0.62 and 1.40±0.58 μg.ml(-1); T(max) were 3.51±0.54 and 2.01±0.42 h; AUC were 7.65±2.54 and 7.12±2.10 μg.h.ml(-1). CONCLUSION: The preparation method is easy and applicable. The self-made CLM dry suspension containing microcapsules sufficiently alleviate the bitterness of commercial CLM dry suspension, but not decrease the bioavailability and have better effect for delaying drug release in healthy volunteers
format Online
Article
Text
id pubmed-3979207
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-39792072014-05-13 Preparation and In Vitro, In Vivo Evaluation of Clarithromycin Microcapsules Hu, Liandong Liu, Wei Li, Li Zhao, Jiqiang Yang, Xun J Basic Clin Pharm Original Article PURPOSE: To develop and validate a method to prepare clarithromycin (CLM) microcapsules to mask the bitter taste and provide effective treatment, and evaluate the quality of microcapsules in detail, especially the in vitro and in vivo pharmacokinetics behavior. METHODS: CLM microcapsules were prepared using ethyl cellulose as matrix material by an emulsion solvent diffusion method. The physicochemical property, in vitro release study, sensory test and stability test were evaluated. Self-made CLM dry suspension or conventional tablets containing 250 mg of CLM were orally administered with 250 mL of water. The plasma concentration was determined and the pharmacokinetic parameters were calculated by non-compartmental methods. RESULTS: Stable microcapsules could be prepared using ethyl cellulose as matrix material. The quality evaluation of prepared microcapsules was qualified, and the pharmacokinetic parameters of dry suspensions and conventional tablets were as following. C(max) were 1.32±0.62 and 1.40±0.58 μg.ml(-1); T(max) were 3.51±0.54 and 2.01±0.42 h; AUC were 7.65±2.54 and 7.12±2.10 μg.h.ml(-1). CONCLUSION: The preparation method is easy and applicable. The self-made CLM dry suspension containing microcapsules sufficiently alleviate the bitterness of commercial CLM dry suspension, but not decrease the bioavailability and have better effect for delaying drug release in healthy volunteers Medknow Publications & Media Pvt Ltd 2010-12 2011-02-15 /pmc/articles/PMC3979207/ /pubmed/24825996 Text en Copyright: © Journal of Basic and Clinical Pharmacy http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Hu, Liandong
Liu, Wei
Li, Li
Zhao, Jiqiang
Yang, Xun
Preparation and In Vitro, In Vivo Evaluation of Clarithromycin Microcapsules
title Preparation and In Vitro, In Vivo Evaluation of Clarithromycin Microcapsules
title_full Preparation and In Vitro, In Vivo Evaluation of Clarithromycin Microcapsules
title_fullStr Preparation and In Vitro, In Vivo Evaluation of Clarithromycin Microcapsules
title_full_unstemmed Preparation and In Vitro, In Vivo Evaluation of Clarithromycin Microcapsules
title_short Preparation and In Vitro, In Vivo Evaluation of Clarithromycin Microcapsules
title_sort preparation and in vitro, in vivo evaluation of clarithromycin microcapsules
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979207/
https://www.ncbi.nlm.nih.gov/pubmed/24825996
work_keys_str_mv AT huliandong preparationandinvitroinvivoevaluationofclarithromycinmicrocapsules
AT liuwei preparationandinvitroinvivoevaluationofclarithromycinmicrocapsules
AT lili preparationandinvitroinvivoevaluationofclarithromycinmicrocapsules
AT zhaojiqiang preparationandinvitroinvivoevaluationofclarithromycinmicrocapsules
AT yangxun preparationandinvitroinvivoevaluationofclarithromycinmicrocapsules